Systemic inflammation in COPD

Clinical Pulmonary Medicine

Volumn 16, Issue 5, 2009, Pages 233-242

  Gea, Joaquim ^a   Barreiro, Esther ^b   Orozco Levi, Mauricio ^b  

^a HOSPITAL DEL MAR   (Spain)

^b NONE

Author keywords

Copd; Oxidative stress; Systemic inflammation; Tobacco smoking

Indexed keywords

ACETYLCYSTEINE; ADENOSINE PHOSPHATE; ALPHA 1 ANTITRYPSIN; ANTIOXIDANT; BRONCHODILATING AGENT; C REACTIVE PROTEIN; FIBRINOGEN; GAMMA INTERFERON; HOMOCYSTEINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INFLIXIMAB; INTERLEUKIN 1; INTERLEUKIN 6; INTERLEUKIN 8; LEPTIN; N ACYSTELYN; REACTIVE OXYGEN METABOLITE; ROFLUMILAST; STEROID; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ATHEROSCLEROSIS; BLOOD CLOTTING DISORDER; BODY COMPOSITION; BONE METABOLISM; CALCIUM METABOLISM; CARDIOVASCULAR DISEASE; CD8+ T LYMPHOCYTE; CENTRAL NERVOUS SYSTEM DISEASE; CHRONIC BRONCHITIS; CHRONIC INFLAMMATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; DISEASE ASSOCIATION; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG MECHANISM; DRUG MEGADOSE; DYSPNEA; ELECTROLYTE BALANCE; EXERCISE INTENSITY; FLUID BALANCE; HEMOSTASIS; HUMAN; HYPOGONADISM; INFLAMMATION; KIDNEY BLOOD FLOW; KIDNEY DYSFUNCTION; LEUKOCYTE COUNT; LUNG EMPHYSEMA; MONOCYTE; MUSCLE DISEASE; MUSCLE FUNCTION; NEUTROPHIL; NUTRITIONAL DEFICIENCY; OSTEOARTHROPATHY; OSTEOPOROSIS; OXIDATIVE STRESS; PATHOGENESIS; PATHOPHYSIOLOGY; PHOSPHATE METABOLISM; PHYSICAL ACTIVITY; PNEUMONIA; PROTEIN BLOOD LEVEL; PULMONARY HYPERTENSION; REVIEW; SEX DIFFERENCE; SEXUAL DYSFUNCTION; SKELETAL MUSCLE; SMOKING HABIT; SODIUM BALANCE; URINARY TRACT DISEASE;

EID: 70349662322     PISSN: 10680640     EISSN: None     Source Type: Journal    
DOI: 10.1097/CPM.0b013e3181bc3bb7     Document Type: Review

References (186)

1. Murray CJ, Lopez AD. Evidence-based health policy. Lessons from the Global Burden of Disease Study. Science. 1996;274:740-743.
2. Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary Disease. NHLBI/WHO workshop report. Bethesda, National Heart, Lung and Blood Institute. Update of the Management Sections. Available at: http://www.goldcopd. com. Accessed August 18, 2008.
3. Celli BR, MacNee W; ATS/ERS Task Force. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J. 2004;23:932-946.
4. Agustí AG, Noguera A, Sauleda J, et al. Systemic effects of chronic obstructive pulmonary disease. Eur Respir J. 2003;21:347-360. (Pubitemid 36204553)
5. Gan WQ, Man SF, Senthilselvan A, et al. Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis. Thorax. 2004;59:574-580. (Pubitemid 38901515)
6. American Thoracic Society and European Respiratory Society. Skeletal muscle dysfunction in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1999;159(suppl):S1-S40.
7. Barreiro E, De la Puente B, Minguella J, et al. Oxidative stress and respiratory muscle dysfunction in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2005;171:1116-1124. (Pubitemid 40663723)
8. Schols AM, Buurman WA, Staal van den Brekel AJ, et al. Evidence for a relation between metabolic derangements and increased levels of inflammatory mediators in a subgroup of patients with chronic obstructive pulmonary disease. Thorax. 1996;51:819-824.
9. Creutzberg EC, Schols AM, Bothmer-Quaedvlieg FC, et al. Prevalence of an elevated resting energy expenditure in patients with chronic obstructive pulmonary disease in relation to body composition and lung function. Eur J Clin Nutr. 1998;52:396-401.
10. Anand IS, Chandrashekhar Y, Ferrari R, et al. Pathogenesis of congestive state in chronic obstructive pulmonary disease. Studies of body water and sodium, renal function, hemodynamics, and plasma hormones during edema and after recovery. Circulation. 1992;86:12-21.
11. Palange P. Renal and hormonal abnormalities in chronic obstructive pulmonary disease (COPD). Thorax. 1998;53:989-991. (Pubitemid 28494342)
12. Raisz LG. Physiology and pathophysiology of bone remodeling. Clin Chem. 1999;45:1353-1358.
13. Ionescu AA, Schoon E. Osteoporosis in chronic obstructive pulmonary disease. Eur Respir J. 2003;22(suppl 46):64s-75s. (Pubitemid 37351738)
14. Mathur R, Cox IJ, Oatridge A, et al. Cerebral bioenergetics in stable chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1999;160: 1994-1999. (Pubitemid 30004709)
15. Hamilton G, Mathur R, Allsop JM, et al. Changes in brain intracellular pH and membrane phospholipids on oxygen therapy in hypoxic patients with chronic obstructive pulmonary disease. Metab Brain Dis. 2003;18: 95-109. (Pubitemid 36207340)
16. Creutzberg EC, Casaburi R. Endocrinological disturbances in chronic obstructive pulmonary disease. Eur Respir J. 2003;46(suppl):76s- 80s. (Pubitemid 37351739)
17. Hjalmarsen A, Aasebo U, Birkeland K, et al. Impaired glucose tolerance in patients with chronic hypoxic pulmonary disease. Diabetes Metab. 1996;22: 37-42. (Pubitemid 26120842)
18. Rabe KF, Beghé B, Luppi F, et al. Update in chronic obstructive pulmonary disease 2006. Am J Respir Crit Care Med. 2007;175:1222-1232.
19. Fabbri LM, Rabe KF. From COPD to chronic systemic inflammatory syndrome? Lancet. 2007;370:797-799. (Pubitemid 47320803)
20. Fabbri LM, Luppi F, Beghé B, et al. Complex chronic comorbidities of COPD. Eur Respir J. 2008;31:204-212.
21. Gea J, Barreiro E, Orozco-Levi M. Free radicals, cytokines, and respiratory muscles in COPD patients. Clin Pulm Med. 2007;14:117-126. (Pubitemid 46763347)
22. Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Eng J Med. 1999;340:448-454. (Pubitemid 29084777)
23. Oudijk EJ, Lammers JW, Koenderman L. Systemic inflammation in chronic obstructive pulmonary disease. Eur Respir J. 2003;22(suppl 46):5s-13s. (Pubitemid 37351732)
24. Saetta M, Turato G, Facchini FM, et al. Inflammatory cells in the bronchial glands of smokers with chronic bronchitis. Am J Respir Crit Care Med. 1997;156:1633-1639. (Pubitemid 27505536)
25. Di Stefano A, Capelli A, Lusuardi M, et al. Severity of airflow limitation is associated with severity of airway inflammation in smokers. Am J Respir Crit Care Med. 1998;158:1277-1285. (Pubitemid 28489033)
26. Lim S, Roche N, Oliver BG, et al. Balance of matrix metalloprotease-9 and tissue inhibitor of metalloprotease-1 from alveolar macrophages in cigarette smokers: regulation by interleukin-10. Am J Respir Crit Care Med. 2000; 162:1355-1360. (Pubitemid 30826154)
27. Tetley TD. Macrophages and the pathogenesis of COPD. Chest 2002; 121(suppl 5):156S-159S.
28. Capelli A, Di Stefano A, Gnemmi I, et al. Increased MCP-1 and MIP-1beta in bronchoalveolar lavage fluid of chronic bronchitics. Eur Respir J. 1999; 14:160-165. (Pubitemid 29411251)
29. Tomita K, Caramori G, Lim S, et al. Increased p21(CIP1/WAF1) and B cell lymphoma leukemia-x(L) expression and reduced apoptosis in alveolar macrophages from smokers. Am J Respir Crit Care Med. 2002;166:724-731. (Pubitemid 34971857)
30. Majó J, Ghezzo H, Cosio MG. Lymphocyte population and apoptosis in the lungs of smokers and their relation to emphysema. Eur Respir J. 2001;17: 946-953. (Pubitemid 32600344)
31. + cells in the lungs of smokers with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1999;160:711-717.
32. Kim WD, Kim WS, Koh Y, et al. Abnormal peripheral blood T-lymphocyte subsets in a subgroup of patients with COPD. Chest. 2002;122:437-444. (Pubitemid 35002118)
33. Shapiro SD. The macrophage in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1999;160:S29-S32.
34. Hill AT, Campbell EJ, Hill SL, et al. Association between airway bacterial load and markers of airway inflammation in patients with stable chronic bronchitis. Am J Med. 2000;109:288-295.
35. Cosio MG, Majo J, Cosio MG. Inflammation of the airways and lung parenchyma in COPD: role of T cells. Chest. 2002;121:S160-S165. (Pubitemid 34497335)
36. Terashima T, Wiggs B, English D, et al. Phagocytosis of small carbon particles (PM10) by alveolar macrophages stimulates the release of polymorphonuclear leukocytes from bone marrow. Am J Respir Crit Care Med. 1997;155:1441-1447. (Pubitemid 27172795)
37. MacNee W, Wiggs B, Belzberg AS, et al. The effect of cigarette smoking on neutrophil kinetics in human lungs. N Engl J Med. 1989;321:924-928. (Pubitemid 19244050)
38. Sato E, Koyama S, Takamizawa A, et al. Smoke extract stimulates lung fibroblasts to release neutrophil and monocyte chemotactic activities. Am J Physiol. 1999;277:L1149-L1157. (Pubitemid 30046042)
39. Condliffe AM, Kitchen E, Chilvers ER. Neutrophil priming: pathophysiological consequences and underlying mechanisms. Clin Sci (Lond). 1998; 94:461-471. (Pubitemid 28205909)
40. Churg A, Zay K, Shay S, et al. Acute cigarette smoke-induced connective tissue breakdown requires both neutrophils and macrophage metalloelastase in mice. Am J Respir Cell Mol Biol. 2002;27:368-374. (Pubitemid 34979296)
41. Sommerhoff CP, Nadel JA, Basbaum CB, et al. Neutrophil elastase and cathepsin G stimulate secretion from cultured bovine airway gland serous cells. J Clin Invest. 1990;85:682-689.
42. Zhu J, Majumdar S, Qiu Y, et al. Interleukin-4 and interleukin-5 gene expression and inflammation in the mucus-secreting glands and subepithelial tissue of smokers with chronic bronchitis: lack of relationship with CD8+ cells. Am J Respir Crit Care Med. 2001;164:2220-2228. (Pubitemid 34032939)
43. di Francia M, Barbier D, Mege JL, et al. Tumor necrosis factor-alpha levels and weight loss in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1994;150:1453-1455 (Pubitemid 24356667)
44. Eid AA, Ionescu AA, Nixon LS, et al. Inflammatory response and body composition in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2001;164:1414-1418. (Pubitemid 33124019)
45. Karadag F, Kirdar S, Karul AB, et al. The value of C-reactive protein as a marker off systemic inflammation in stable chronic obstructive pulmonary disease. Eur J Inter Med. 2008;19:104-108.
46. Reid MB, Lannergren J, Westerblad H. Respiratory and limb muscle weakness induced by tumor necrosis factor-alpha: involvement of muscle myofilaments. Am J Respir Crit Care Med. 2002;166:479-484. (Pubitemid 34895432)
47. Broekhuizen R, Grimble RF, Howell WM, et al. Pulmonary cachexia, systemic inflammatory profile, and the interleukin 1beta -511 single nucleotide polymorphism. Am J Clin Nutr. 2005;82:1059-1064. (Pubitemid 43779765)
48. Broekhuizen R, Vernooy JH, Schols AM, et al. Leptin as local inflammatory marker in COPD. Respir Med. 2005;99:70-74. (Pubitemid 40017387)
49. Tomoda K, Yoshikawa M, Itoh T, et al. Elevated circulating plasma adiponectin in underweight patients with COPD. Chest. 2007;132:135-140. (Pubitemid 47068213)
50. van Helvoort HA, Heijdra YF, Heunks LM, et al. Supplemental oxygen prevents exercise-induced oxidative stress in muscle-wasted patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2006; 173:1122-1129. (Pubitemid 43726893)
51. Casadevall C, Coronell C, Ramírez-Sarmiento AL, et al. Upregulation of pro-inflammatory cytokines in the intercostal muscles of COPD patients. Eur Respir J. 2007;30:701-707. (Pubitemid 351194830)
52. Barreiro E, Schols AM, Polkey MI, et al. Cytokine profile in quadriceps muscles of patients with severe COPD. Thorax. 2008;63:100-107. (Pubitemid 351236469)
53. Agustí AG, Sauleda J, Miralles C, et al. Skeletal muscle apoptosis and weight loss in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2002;166:485-489. (Pubitemid 34895433)
54. Maltais F, Sullivan MJ, LeBlanc P, et al. Altered expression of myosin heavy chain in the vastus lateralis muscle in patients with COPD. Eur Respir J. 1999;13:850-854. (Pubitemid 29234790)
55. Montes de Oca M, Torres SH, De Sanctis J, et al. Skeletal muscle inflammation and nitric oxide in patients with COPD. Eur Respir J. 2005;26:390-397. (Pubitemid 41264199)
56. Gosker HR, Kubat B, Schaart G, et al. Myopathological features in skeletal muscle of patients with chronic obstructive pulmonary disease. Eur Respir J. 2003;22:280-285. (Pubitemid 36986998)
57. Joppa P, Petrasova D, Stancak B, et al. Systemic inflammation in patients with COPD and pulmonary hypertension. Chest. 2006;130:326-333. (Pubitemid 44266997)
58. Sin DD, Man SF. Systemic inflammation and mortality in chronic obstructive pulmonary disease. Can J Physiol Pharmacol. 2007;85:141-147. (Pubitemid 46996112)
59. McGarvey LP, John M, Anderson JA, et al. Ascertainment of cause-specific mortality in COPD: operations of the TORCH Clinical Endpoint Committee. Thorax. 2007;62:411-415. (Pubitemid 46698390)
60. Mannino DM, Ford ES, Redd SC. Obstructive and restrictive lung disease and markers of inflammation: data from the Third National Health and Nutrition Examination. Am J Med. 2003;114:758-762. (Pubitemid 36776358)
61. Ashitani J, Mukae H, Arimura Y, et al. Elevated plasma procoagulant and fibrinolytic markers in patients with chronic obstructive pulmonary disease. Intern Med. 2002;41:181-185. (Pubitemid 34285434)
62. Wedzicha JA, Syndercombe-Court D, Tan KC. Increased platelet aggregate formation in patients with chronic airflow obstruction and hypoxaemia. Thorax. 1991;46:504-507.
63. Ferroni P, Basili S, Alessandri C, et al. Proinflammatory cytokines and hemostatic system in patients with chronic obstructive pulmonary disease. Platelets. 1997;8:255-259. (Pubitemid 27432390)
64. Riancho JA, González Macías J, Del Arco C, et al. Vertebral compression fractures and mineral metabolism in chronic obstructive lung disease. Thorax. 1987;42:962-966. (Pubitemid 18030876)
65. Dubois EF, Röder E, Dekhuijzen PN, et al. Dual energy x-ray absorptiometry outcomes in male COPD patients after treatment with different glucocorticoid regimens. Chest. 2002;121:1456-1463. (Pubitemid 34499655)
66. Howes TQ, Deane CR, Levin GE, et al. The effects of oxygen and dopamine on renal and aortic blood flow in chronic obstructive pulmonary disease with hypoxemia and hypercapnia. Am J Respir Crit Care Med. 1995;151:378-383.
67. Skwarski K, Lee M, Turnbull L, et al. Atrial natriuretic peptide in stable and decompensated chronic obstructive pulmonary disease. Thorax. 1993;48: 730-735. (Pubitemid 23214867)
68. de Leeuw PW, Dees A. Fluid homeostasis in chronic obstructive lung disease. Eur Respir J. 2003;22(suppl 46):33s- 40s. (Pubitemid 37351735)
69. Karadag F, Ozcan H, Karul AB, et al. Sex hormone alterations and systemic inflammation in chronic obstructive pulmonary disease. Int J Clin Pract. 2009;63:275-281.
70. Mador MJ, Bozkanat E. Skeletal muscle dysfunction in chronic obstructive pulmonary disease. Respir Res. 2001;2:216-224. (Pubitemid 34187929)
71. Burdet L, de Muralt B, Schutz Y, et al. Administration of growth hormone to underweight patients with chronic obstructive pulmonary disease: a prospective, randomized, controlled study. Am J Respir Crit Care Med. 1997;156:1800-1806. (Pubitemid 28011785)
72. Pape GS, Friedman M, Underwood LE, et al. The effect of growth hormone on weight gain and pulmonary function in patients with chronic obstructive lung disease. Chest. 1991;99:1495-1500.
73. Dimopoulou I, Ilias I, Mastorakos G, et al. Effects of severity of chronic obstructive pulmonary disease on thyroid function. Metabolism. 2001;50: 1397-1401. (Pubitemid 34007407)
74. Vincent EE, Singh SJ, Review article: addressing the sexual health of patients with COPD: the needs of the patient and implications for health care professionals. Chron Respir Dis. 2007;4:111-115.
75. Mohamed-Hussein AA, Hamed SA, Abdel-Hakim N. Cerebral cortical dysfunction in chronic obstructive pulmonary disease: role of transcranial magnetic stimulation. Int J Tuberc Lung Dis. 2007;11:515-521. (Pubitemid 46732637)
76. Donaldson GC, Seemungal TA, Patel IS, et al. Airway and systemic inflammation and decline in lung function in patients with COPD. Chest. 2005;128:1995-2004. (Pubitemid 41507533)
77. Michel O, Dentener M, Corazza F, et al. Healthy subjects express differences in clinical responses to inhaled lipopolysaccharide that are related with inflammation and with atopy. J Allergy Clin Immunol. 2001;107:797-804. (Pubitemid 32436912)
78. Zhang J, Liu Y, Shi J, et al. Side-stream cigarette smoke induces dose-response in systemic inflammatory cytokine production and oxidative stress. Exp Biol Med (Maywood). 2002;227:823-829.
79. Andreassen H, Vestbo J. Chronic obstructive pulmonary disease as a systemic disease: an epidemiological perspective. Eur Respir J Suppl. 2003;46:2s- 4s. (Pubitemid 37351731)
80. Orozco-Levi M, Garcia-Aymerich J, Villar J, et al. Wood smoke exposure and risk of chronic obstructive pulmonary disease. Eur Respir J. 2006;27: 542-546. (Pubitemid 43372528)
81. Swiston JR, Davidson W, Attridge S, et al. Wood smoke exposure induces a pulmonary and systemic inflammatory response in firefighters. Eur Respir J. 2008;32:129-138.
82. van Eeden SF, Tan WC, Suwa T, et al. Cytokines involved in the systemic inflammatory response induced by exposure to particulate matter air pollutants (PM(10)). Am J Respir Crit Care Med. 2001;164:826-830. (Pubitemid 32881920)
83. Yu AY, Frid MG, Shimoda LA, et al. Temporal, spatial, and oxygen-regulated expression of hypoxia-inducible factor-1 in the lung. Am J Physiol. 1998;275:L818-L826. (Pubitemid 28491865)
84. Dahl M, Tybjaerg-Hansen A, Vestbo J, et al. Elevated plasma fibrinogen associated with reduced pulmonary function and increased risk of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2001;164: 1008-1011. (Pubitemid 32971649)
85. Hageman GJ, Larik I, Pennings HJ, et al. Systemic poly(ADP-ribose) polymerase-1 activation, chronic inflammation, and oxidative stress in COPD patients. Free Radic Biol Med. 2003;35:140-148. (Pubitemid 36835914)
86. Valipour A, Schreder M, Wolzt M, et al. Circulating vascular endothelial growth factor and systemic inflammatory markers in patients with stable and exacerbated chronic obstructive pulmonary disease. Clin Sci (Lond). 2008; 115:225-232.
87. Hill AT, Campbell EJ, Bayley DL, et al. Evidence for excessive bronchial inflammation during an acute exacerbation of chronic obstructive pulmonary disease in patients with alpha(1)-antitrypsin deficiency (PiZ). Am J Respir Crit Care Med. 1999;160:1968-1975.
88. Pasceri V, Willerson JT, Yeh ET. Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation. 2000;102:2165-2168. (Pubitemid 30808000)
89. Cirillo DJ, Agrawal Y, Cassano PA. Lipids and pulmonary function in the Third National Health and Nutrition Examination Survey. Am J Epidemiol. 2002;155:842-848. (Pubitemid 34456995)
90. Franciosi LG, Page CP, Celli BR, et al. Markers of disease severity in chronic obstructive pulmonary disease. Pulm Pharmacol Ther. 2006;19: 189-199.
91. Broekhuizen R, Wouters EF, Creutzberg EC, et al. Raised CRP levels mark metabolic and functional impairment in advanced COPD. Thorax. 2006;61: 17-22. (Pubitemid 43106972)
92. Cano NJ, Pichard C, Roth H, et al. C-reactive protein and body mass index predict outcome in end-stage respiratory failure. Chest. 2004;126:540-546. (Pubitemid 39093441)
93. Sin DD, Lacy P, York E, et al. Effects of fluticasone on systemic markers of inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2004;170:760-765. (Pubitemid 39298991)
94. Seemungal T, Harper-Owen R, Bhowmik A, et al. Respiratory viruses, symptoms, and inflammatory markers in acute exacerbations and stable chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2001; 164:1618-1623. (Pubitemid 33124148)
95. Gan WQ, Man SF, Sin DD. The interactions between cigarette smoking and reduced lung function on systemic inflammation. Chest. 2005;127:558-564. (Pubitemid 40229317)
96. Calikoglu M, Sahin G, Unlu A, et al. Leptin and TNF-alpha levels in patients with chronic obstructive pulmonary disease and their relationship to nutritional parameters. Respiration. 2004;71:45-50. (Pubitemid 38223765)
97. Tracey KJ, Cerami A. Metabolic responses to cachectin/TNF: a brief review. Ann NY Acad Sci. 1990 587:325-331. (Pubitemid 20249304)
98. Hauner H, Petruschke T, Russ M, et al. Effects of tumour necrosis factor alpha (TNF alpha) on glucose transport and lipid metabolism of newly-differentiated human fat cells in cell culture. Diabetologia. 1995;38:764-771.
99. Stockley RA, Bayley DL, Unsal I, et al. The effect of augmentation therapy on bronchial inflammation in alpha1-antitrypsin deficiency. Am J Respir Crit Care Med. 2002;165:1494-1498. (Pubitemid 34606663)
100. Welle I, Bakke PS, Eide GE, et al. Increased circulating levels of alpha1-antitrypsin and calprotectin are associated with reduced gas diffusion in the lungs. Eur Respir J. 2001;17:1105-1111. (Pubitemid 32717465)
101. Caldefie-Chezet F, Poulin A, Vasson MP. Leptin regulates functional capacities of polymorphonuclear neutrophils. Free Radic Res. 2003;37:809-814. (Pubitemid 36939597)
102. Loffreda S, Yang SQ, Lin HZ, et al. Leptin regulates proinflammatory immune responses. FASEB J. 1998;12:57-65. (Pubitemid 28060271)
103. Moore SI, Huffnagle GB, Chen GH, et al. Leptin modulates neutrophil phagocytosis of Klebsiella pneumoniae. Infect Immun. 2003;71:4182-4185.
104. Seemungal TA, Lun JC, Davis G, et al. Plasma homocysteine is elevated in COPD patients and is related to COPD severity. Int J Chron Obstruct Pulmon Dis. 2007;2:313-321. (Pubitemid 350110904)
105. Andersson A, Ankerst J, Lindgren A, et al. Hyperhomocysteinemia and changed plasma thiol redox status in chronic obstructive pulmonary disease. Clin Chem Lab Med. 2001;39:229-333. (Pubitemid 32390416)
106. Freedman DS, Flanders WD, Barboriak JJ, et al. Cigarette smoking and leukocyte subpopulations in men. Ann Epidemiol. 1996;6:299-306.
107. Terashima T, Wiggs B, English D, et al. The effect of cigarette smoking on the bone marrow. Am J Respir Crit Care Med. 1997;155:1021-1026. (Pubitemid 27133418)
108. Burnett D, Chamba A, Hill SL, et al. Effects of plasma, tumour necrosis factor, endotoxin and dexamethasone on extracellular proteolysis by neutrophils from healthy subjects and patients with emphysema. Clin Sci (Lond). 1989;77:35-41. (Pubitemid 19154022)
109. Aldonyte R, Jansson L, Piitulainen E, et al. Circulating monocytes from healthy individuals and COPD patients. Respir Res. 2003;4:1-8. (Pubitemid 41358098)
110. Sauleda J, Garcia-Palmer FJ, Gonzalez G, et al. The activity of cytochrome oxidase is increased in circulating lymphocytes of patients with chronic obstructive pulmonary disease, asthma, and chronic arthritis. Am J Respir Crit Care Med. 2000;161:32-35. (Pubitemid 30055899)
111. De Jong JW, Belt-Gritter B, Koeter GH, et al. Peripheral blood lymphocyte cell subsets in subjects with chronic obstructive pulmonary disease: association with smoking, IgE and lung function. Respir Med. 1997;91:67-76. (Pubitemid 27107669)
112. van Helvoort HA, van de Pol MH, Heijdra YF, et al. Systemic inflammatory response to exhaustive exercise in patients with chronic obstructive pulmonary disease. Respir Med. 2005;99:1555-1567. (Pubitemid 41683936)
113. MacKnee W. Pulmonary and systemic oxidant/antioxidant imbalance in chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2005;2:50-60. (Pubitemid 40562963)
114. Langen RC, Korn SH, Wouters EF. ROS in the local and systemic pathogenesis of COPD. Free Radic Biol Med. 2003;35:226-235.
115. Rahman I, Morrison D, Donaldson K, et al. Systemic oxidative stress in asthma, COPD, and smokers. Am J Respir Crit Care Med. 1996;154:1055-1060. (Pubitemid 126679546)
116. Rahman I, Swarska E, Henry M, et al. Is there any relationship between plasma antioxidant capacity and lung function in smokers and in patients with chronic obstructive pulmonary disease? Thorax. 2000;55:189-193. (Pubitemid 30245967)
117. Kosmas EN, Zorpidou D, Vassilareas V, et al. Decreased C4 complement component serum levels correlate with the degree of emphysema in patients with chronic bronchitis. Chest. 1997;112:341-347. (Pubitemid 27349422)
118. Hodge SJ, Hodge GL, Reynolds PN, et al. Increased production of TGF-ß and apoptosis of T lymphocytes isolated from peripheral blood in COPD. Am J Physiol Lung Cell Mol Physiol. 2003;285:L492-L499.
119. Noguera A, Busquets X, Sauleda J, et al. Expression of adhesion molecules and G proteins in circulating neutrophils in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1998;158:1664-1668. (Pubitemid 28536634)
120. Creutzberg EC, Schols AM, Weling-Scheepers CA, et al. Characterization of nonresponse to high caloric oral nutritional therapy in depleted patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2000;161:745-752.
121. Wouters EF, Groenewegen KH, Dentener MA, et al. Systemic inflammation in chronic obstructive pulmonary disease: the role of exacerbations. Proc Am Thorac Soc. 2007;4:626-634. (Pubitemid 350291625)
122. Hurst JR, Perera WR, Wilkinson TM, et al. Exacerbation of chronic obstructive pulmonary disease: pan-airway and systemic inflammatory indices. Proc Am Thorac Soc. 2006;3:481-482. (Pubitemid 44285524)
123. Pinto-Plata VM, Livnat G, Girish M, et al. Systemic cytokines, clinical and physiological changes in patients hospitalized for exacerbation of COPD. Chest. 2007;131:37-43. (Pubitemid 46122972)
124. Fiorini G, Crespi S, Rinaldi M, et al. Serum ECP and MPO are increased during exacerbations of chronic bronchitis with airway obstruction. Biomed Pharmacother. 2000;54:274-278. (Pubitemid 30432097)
125. Roland M, Bhowmik A, Sapsford RJ, et al. Sputum and plasma endothelin-1 levels in exacerbations of chronic obstructive pulmonary disease. Thorax. 2001;56:30-35. (Pubitemid 32041716)
126. Hurst JR, Donaldson GC, Perera WR, et al. Use of plasma biomarkers at exacerbation of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2006;174:867-874. (Pubitemid 44564786)
127. Takabatake N, Nakamura H, Abe S, et al. Circulating leptin in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1999; 159:1215-1219. (Pubitemid 29202558)
128. Porteu F, Nathan C. Shedding of tumor necrosis factor receptors by activated human neutrophils. J Exp Med. 1990;172:599-607. (Pubitemid 20248401)
129. Takabatake N, Nakamura H, Abe S, et al. The relationship between chronic hypoxemia and activation of the tumor necrosis factor-α system in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2000;161:1179-1184. (Pubitemid 30243827)
130. Li YP, Reid MB. Effect of tumor necrosis factor-alpha on skeletal muscle metabolism. Curr Opin Rheumatol. 2001;13:483-487. (Pubitemid 33070964)
131. Grunfeld C, Zhao C, Fuller J, et al. Endotoxin and cytokines induce expression of leptin, the ob gene product, in hamsters. J Clin Invest. 1996;97:2152-2157.
132. Pedersen BK. IL-6 signalling in exercise and disease. Biochem Soc Trans. 2007;35:1295-1297.
133. Serrano AL, Baeza-Raja B, Perdiguero E, et al. Interleukin-6 is an essential regulator of satellite cell-mediated skeletal muscle hypertrophy. Cell Metab. 2008;7:33-44.
134. Chung KF. Cytokines in chronic obstructive pulmonary disease. Eur Respir J. 2001;18(suppl 34):50s-59s.
135. Argiles JM, López-Soriano FJ. The role of cytokines in cancer cachexia. Med Res Rev. 1999;19:223-248.
136. Lappalainen U, Whitsett JA, Wert SE, et al. Interleukin-1beta causes pulmonary inflammation, emphysema, and airway remodeling in the adult murine lung. Am J Respir Cell Mol Biol. 2005;32:311-318. (Pubitemid 40478306)
137. Keatings VM, Collins PD, Scott DM, et al. Differences in interleukin-8 and tumor necrosis factor-alpha in induced sputum from patients with chronic obstructive pulmonary disease or asthma. Am J Respir Crit Care Med. 1996;153:530-534. (Pubitemid 126423950)
138. Sierra-Honigmann MR, Nath AK, Murakami C, et al. Biological action of leptin as an angiogenic factor. Science. 1998;281:1683-1686. (Pubitemid 28435586)
139. Masabuchi T, Koyama S, Sato E, et al. Smoke extract stimulates lung epithelial cells to release neutrophil and monocyte chemotactic activity. Am J Pathol. 1998;153:1903-1912. (Pubitemid 28550677)
140. Bergmann S, Siekmeier R, Mix C, et al. Even moderate cigarette smoking influences the pattern of circulating monocytes and the concentration of sICAM-1. Respir Physiol. 1998;114:269-275. (Pubitemid 29050874)
141. Parks DA, Granger DN. Ischemia-induced vascular changes: role of xanthine oxidase and hydroxyl radicals. Am J Physiol. 1983;245:G285-G289.
142. Kumada M, Kihara S, Ouchi N, et al. Adiponectin specifically increased tissue inhibitor of metalloproteinase-1 through interleukin-10 expression in human macrophages. Circulation. 2004;109:2046-2049. (Pubitemid 38620209)
143. Wolf AM, Wolf D, Rumpold H, et al. Adiponectin induces the anti-inflammatory cytokines IL-10 and IL-1RA in human leukocytes. Biochem Biophys Res Commun. 2004;323:630-635. (Pubitemid 39221142)
144. Szmitko PE, Wang CH, Weisel RD, et al. New markers of inflammation and endothelial cell activation: part I. Circulation. 2003;108:1917-1923. (Pubitemid 37296533)
145. Sin DD, Man SF. Is systemic inflammation responsible for pulmonary hypertension in COPD? Chest. 2006;130:310-312. (Pubitemid 44266992)
146. Mills NL, Miller JJ, Anand A, et al. Increased arterial stiffness in patients with chronic obstructive pulmonary disease: a mechanism for increased cardiovascular risk. Thorax. 2008;63:306-311.
147. Wang CH, Li SH, Weisel RD, et al. C-reactive protein upregulates angiotensin type 1 receptors in vascular smooth muscle. Circulation. 2003;107: 1783-1790. (Pubitemid 36418360)
148. Verma S, Badiwala MV, Weisel RD, et al. C-reactive protein activates the nuclear factor-kappaB signal transduction pathway in saphenous vein endothelial cells: implications for atherosclerosis and restenosis. J Thorac Cardiovasc Surg. 2003;126:1886-1891. (Pubitemid 38020747)
149. Beltowski J. Leptin and atherosclerosis. Atherosclerosis. 2006;189:47-60.
150. Sabit R, Bolton CE, Edwards PH, et al. Arterial stiffness and osteoporosis in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2007; 175:1259-1265. (Pubitemid 46905751)
151. Castagna O, Boussuges A, Nussbaum E, et al. Peripheral arterial disease: an underestimated aetiology of exercise intolerance in chronic obstructive pulmonary disease patients. Eur J Cardiovasc Prev Rehabil. 2008;15:270-277.
152. Li YP, Schwartz RJ, Waddell ID, et al. Skeletal muscle myocytes undergo protein loss and reactive oxygen-mediated NF-κB activation in response to tumor necrosis factor α. FASEB J. 1998;12:871-880.
153. Cabane C, Englaro W, Yeow K, et al. Regulation of C2C12 myogenic terminal differentiation by MKK3/p38alpha pathway. Am J Physiol Cell Physiol. 2003;284:C658-C666. (Pubitemid 36237518)
154. Esmon CT. The interactions between inflammation and coagulation. 2005; 131:417-430.
155. Brodsky IG, Balagopal P, Nair KS. Effects of testosterone replacement on
156. van der Poll T, Romijn JA, Endert E, et al. Effects of tumor necrosis factor on the hypothalamic-pituitary-testicular axis in healthy men. Metabolism. 1993;42:303-307. (Pubitemid 23073346)
157. Nyström F, Ekman B, Osterlund M, et al. Serum leptin concentrations in a normal population and in GH deficiency: negative correlation with testosterone in men and effects of GH treatment. Clin Endocrinol (Oxf). 1997; 47:191-198. (Pubitemid 27359899)
158. Garcia-Aymerich J, Lange P, Benet M, et al. Regular physical activity reduces hospital admission and mortality in chronic obstructive pulmonary disease: a population based cohort study. Thorax. 2006;61:772-778. (Pubitemid 44369401)
159. Petersen AM, Pedersen BK. The role of IL-6 in mediating the anti-inflammatory effects of exercise. J Physiol Pharmacol. 2006;57(suppl 10): 43-51. (Pubitemid 46548766)
160. Abramson JL, Vaccarino V. Relationship between physical activity and inflammation among apparently healthy middle-aged and older US adults. Arch Intern Med. 2002;162:1286-1292. (Pubitemid 34595035)
161. Rabe KF. Improving dyspnea in chronic obstructive pulmonary disease: optimal treatment strategies. Proc Am Thorac Soc. 2006;3:270-275. (Pubitemid 43668193)
162. Petersen AM, Pedersen BK. The anti-inflammatory effect of exercise. J Appl Physiol. 2005;98:1154-1162.
163. Wang P, Wu P, Siegel MI, et al. IL-10 inhibits transcription of cytokine genes in human peripheral blood mononuclear cells. J Immunol. 1994;153: 811-816. (Pubitemid 24206311)
164. Dinarello CA. The role of the interleukin-1-receptor antagonist in blocking inflammation mediated by interleukin-1. N Engl J Med. 2000;343:732-734.
165. Febbraio MA, Pedersen BK. Muscle-derived interleukin-6: mechanisms for activation and possible biological roles. FASEB J. 2002;16:1335-1347.
166. El-Zayadi AR. Heavy smoking and liver. World J Gastroenterol. 2006;12: 6098-6101.
167. Buist AS, Vollmer WM, McBurnie MA. Worldwide burden of COPD in high- and low-income countries. Part I: the burden of obstructive lung disease (BOLD) initiative. Int J Tuberc Lung Dis. 2008;12:703-708. (Pubitemid 351976696)
168. Olafsdóttir IS, Gíslason T, Thjódleifsson B, et al. Gender differences in the association between C-reactive protein, lung function impairment, and COPD. Int J Chron Obstruct Pulmon Dis. 2007;2:635-642.
169. Yang IA, Fong KM, Sim EH, et al. Inhaled corticosteroids for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2007;2: CD002991.
170. Soriano JB, Sin DD, Zhang X, et al. A pooled analysis of FEV1 decline in COPD patients randomized to inhaled corticosteroids or placebo. Chest. 2007;131:682-689. (Pubitemid 46446857)
171. Barnes PJ. Potential novel therapies for chronic obstructive pulmonary disease. Novartis Found Symp. 2001;234:255-267.
172. Chung KF. Cytokines as targets in chronic obstructive pulmonary disease. Curr Drug Targets. 2006;7:675-681. (Pubitemid 43827263)
173. van der Vaart H, Koëter GH, Postma DS, et al. First study of infliximab treatment in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2005;172:465-469. (Pubitemid 41121991)
174. Rennard SI, Fogarty C, Kelsen S, et al. The safety and efficacy of infliximab in moderate to severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2007;175:926-934. (Pubitemid 46684703)
175. Gamble E, Grootendorst DC, Brightling CE, et al. Antiinflammatory effects of the phosphodiesterase-4 inhibitor cilomilast (Ariflo) in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2003;168:976-982. (Pubitemid 37267176)
176. Rutten-van Mölken MP, van Nooten FE, Lindemann M, et al. A 1-year prospective cost-effectiveness analysis of roflumilast for the treatment of patients with severe chronic obstructive pulmonary disease. Pharmacoeconomics. 2007;25:695-711. (Pubitemid 47124171)
177. Grootendorst DC, Gauw SA, Verhoosel RM, et al. Reduction in sputum neutrophil and eosinophil numbers by the PDE4 inhibitor roflumilast in patients with COPD. Thorax. 2007;62:1081-1087.
178. Calverley PM, Sanchez-Toril F, McIvor A, et al. Effect of 1-year treatment with roflumilast in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2007;176:154-161. (Pubitemid 47057851)
179. Albert MA, Danielson E, Rifai N, et al. Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. JAMA. 2001;286:64-70. (Pubitemid 32606333)
180. Cazzola M, Matera MG, Rogliani P, et al. Treating systemic effects of COPD. Trends Pharmacol Sci. 2007;28:544-550.
181. Keddissi JI, Younis WG, Chbeir EA, et al. The use of statins and lung function in current and former smokers. Chest. 2007;132:1764-1771.
182. Frost FJ, Petersen H, Tollestrup K, et al. Influenza and COPD mortality protection as pleiotropic, dose-dependent effects of statins. Chest. 2007;131: 1006-1012. (Pubitemid 46608700)
183. Dekhuijzen PN. Antioxidant properties of N-acetylcysteine: their relevance in relation to chronic obstructive pulmonary disease. Eur Respir J. 2004; 23:629-636.
184. Stey C, Steurer J, Bachmann S, et al. The effect of oral N-acetylcysteine in chronic bronchitis: a quantitative systematic review. Eur Respir J. 2000;16: 253-262. (Pubitemid 30624944)
185. Koechlin C, Couillard A, Simard D, et al. Does oxidative stress alter quadriceps endurance in chronic obstructive pulmonary disease? Am J Respir Crit Care Med. 2004;169:1022-1027. (Pubitemid 38543641)
186. Zuin R, Palamidese A, Negrin R, et al. High-dose N-acetylcysteine in patients with exacerbations of chronic obstructive pulmonary disease. Clin Drug Investig. 2005;25:401-408. (Pubitemid 41019987)